N/A
N=34
Post-Traumatic Stress Disorder (PTSD) and Seroquel
Post-Traumatic Stress Disorder
Bottom Line
View on ClinicalTrials.gov: NCT01066156 ↗Enrolled (actual)
34
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint. — 7.3 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Seroquel (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cambridge Health Alliance
- Primary completion
- Mar 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint. |
7.3 | — |
Summary
This 8 weeks study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD.
Eligibility Criteria
Inclusion Criteria
- Provision of written informed consent
- Fluency in English
- A diagnosis of PTSD
- No pregnancy
- Right-handedness
Exclusion Criteria
- Pregnancy or lactation
- Any cognitive impairment that precludes informed consent
- Known intolerance or lack of response to Seroquel
- Previous enrollment or randomization of treatment in the present study
- Participation in another drug trial within 4 weeks prior enrollment into this study
- Patients with Diabetes Mellitus
- History of allergic reaction or hypersensitivity to Seroquel
- Contraindications to magnetic resonance imaging
- Treatment with an effective medication for PTSD
Data sourced from ClinicalTrials.gov (NCT01066156). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.